Airway diseases, which include asthma, chronic obstructive pulmonary disease, bronchiolitis, and bronchiectasis, continue to pose significant health challenges despite advances in diagnosis and management. As our understanding of the underlying mechanisms evolves, future therapeutic strategies are being developed, with a primary focus on precision medicine, targeted biologics, and novel drug delivery systems. PERSONALIZED AND PRECISION MEDICINE The practice of personalized medicine has considerably influenced the management of airway diseases. Advances in genomics, proteomics, and metabolomics are enabling the identification of distinct phenotypes and endotypes in asthma, paving the way for personalized therapies. Biomarker-driven approaches, such as eosinophil counts, periostin levels, and fractional exhaled nitric oxide (FeNO), are increasingly being used to guide biological therapies. ADVANCEMENTS IN BIOLOGIC THERAPIES Biologic therapies, based on monoclonal antibodies targeting key inflammatory pathways, such as interleukin (IL)-4, IL-5, and IL-13, have shown remarkable efficacy in T2-high asthma. Emerging therapeutic strategies in asthma are increasingly targeting upstream epithelial cytokines that initiate airway inflammation. Inhibition of thymic stromal lymphopoietin (TSLP) with agents such as tezepelumab has demonstrated clinically meaningful reductions in exacerbation rates across a broad spectrum of severe asthma phenotypes, including patients with low eosinophil counts or nonallergic disease. Additional alarmin-targeted therapies directed against IL-33 and IL-25 pathways are currently under investigation and may address the unmet therapeutic need in Type-2 low asthma. Small-molecule inhibitors, including Janus kinase inhibitors, Bruton’s tyrosine kinase inhibitors, and phosphodiesterase-4 inhibitors, are also being explored for their ability to modulate intracellular inflammatory signaling pathways. Furthermore, advances in inhaled biologics and novel drug delivery platforms aim to enhance pulmonary targeting while minimizing systemic exposure, although these approaches remain in early translational stages. Collectively, these emerging therapies may expand treatment options beyond conventional type-2-directed biologics in severe asthma. IL-33 is being extensively investigated as a promising therapeutic target for treating allergic diseases. IL-33 regulates signaling and various biological functions, including the induction of pro-inflammatory cytokines, the regulation of cell proliferation, and involvement in tissue remodelling. Recently, IL-33 has been shown to significantly impact allergic diseases, primarily by inducing Th2 immune responses. Etokimab, a humanized immunoglobulin subtype G1/κ monoclonal Ab, is found to inhibit IL 33. INHALED NANOTECHNOLOGY AND DRUG DELIVERY INNOVATIONS Innovations in inhalation devices are being developed and found to be superior in drug delivery and patient compliance. They include multidose Ellipta and a pressurized metered dose device called aerosphere. Nanotechnology-based drug delivery systems are enhancing the precision and bioavailability of inhaled therapies. Inhaled nanoparticles loaded with anti-inflammatory agents, antibiotics, or biologics may provide targeted and sustained drug release, reducing systemic side effects. ARTIFICIAL INTELLIGENCE AND DIGITAL HEALTH IN AIRWAY DISEASE MANAGEMENT The integration of artificial intelligence (AI) and machine learning into clinical practice is improving the early detection and prediction of disease exacerbations. AI-powered digital inhalers and remote monitoring devices facilitate real-time assessment of lung function, medication adherence, and symptom control, leading to personalized interventions. EMERGING THERAPIES IN ASTHMA Asthma research has advanced much through recent insights into the pathophysiology and cellular interactions. Despite implementing the National Asthma Education and Prevention Program (NAEPP) and Global Initiative for Asthma guidelines, 5%–10% of asthma remains refractory to conventional therapy. Asthma is now classified into distinct phenotypes based on its immunological features. Eosinophilic asthma is a well-established phenotype of severe asthma; however, a substantial body of clinical and experimental evidence strongly associates persistent airway inflammation, including the accumulation of neutrophils in the bronchial mucosa, with resistance to corticosteroid therapy. This is identified as non-type-2 immune responses leading to severe asthma and poor response to steroid therapy. Importantly, mainstay therapies are often ineffective in severe asthma, and effective alternatives are urgently needed. Asthma has been conventionally considered a Th2-mediated inflammatory disorder that requires an anti-inflammatory controller therapy. However, it is demonstrated that there are subpopulations of patients in whom standard therapy fails to give a successful response. Many studies proposed a paradigm shift in the characterization of asthma subgroups that may differentially respond to novel therapies1–4 The development of biological formulations targeting specific molecular pathways is a result of an improved understanding of the genetic and molecular mechanisms of asthma pathogenesis over the past few decades.2 Within the type-2 asthma group, there appears to be heterogeneity, including patients with late-onset eosinophilic disease that respond to anti-IL-5 therapy.3 Importantly, targeting one or more cytokines within a particular asthma endotype can potentially improve clinical outcomes in patients with refractory disease. IL-4 and IL-13 have distinct and overlapping roles in asthma pathophysiology. Both cytokines signal through the type 2 IL-4 receptor (IL-4Rα and IL-13Rα1 heterodimer) and are regulated by the master TH2 transcription factor GATA3. IL-4 induces Immunoglobulin E class switching of B cells and is critical for Th2 cell differentiation, whereas IL-13 promotes cellular influx, airway hyperresponsiveness, and remodeling features.2,4,5 The strategy to block both IL-4 and IL-13 signaling in patients with elevated biomarkers of type 2 inflammation was pursued.2,6 The humanized monoclonal antibody, dupilumab, binds to the IL-4R α chain (shared receptor subunit for IL-4 and IL-13) and was evaluated in a prospective study of moderate-to-severe asthmatics with a type 2-high phenotype (sputum or blood eosinophilia ≥3% or 300 cells/µL, respectively). Importantly, the treatment group exhibited significant reductions in asthma exacerbations, as well as improvements in other clinical outcomes, including quality of life and lung function (but not blood eosinophilia), highlighting the importance of targeting a specific asthma endotype with selective therapy.6 A double-blind placebo-controlled trial of 219 uncontrolled adult asthmatics investigated the efficacy of lebrikizumab in all subjects as well as in the type 2-high subgroup defined by elevated serum periostin levels.7 Although the total cohort demonstrated improved forced expiratory volume in 1 second (FEV1) in subjects receiving lebrikizumab compared to placebo, there were no differences in other measured clinical outcomes. However, patients with high serum periostin levels showed significant improvements in FEV1, as well as a reduction in asthma exacerbations, compared with the placebo group. In asthmatics with elevated blood eosinophil levels and marginal asthma control despite treatment with high-dose inhaled or oral glucocorticoids, asthma exacerbations were reduced in those receiving mepolizumab (anti-IL-5 monoclonal antibody) compared with placebo. The treatment group also had improved FEV1, quality of life, and Asthma Control Questionnaire (ACQ) scores.8 Reslizumab is another humanized anti-IL-5 monoclonal antibody in Phase 3 trials that has demonstrated significant reductions in asthma exacerbations in patients with inadequately controlled asthma and elevated blood eosinophil levels.9 Benralizumab, a humanized monoclonal antibody that targets IL-5 receptor α, has been shown in a phase 2b dose-ranging trial to decrease asthma exacerbations in severe eosinophilic asthma and is being approved for treatment.10 Importantly, one dose of benralizumab has been shown to reduce asthma exacerbations in severe asthmatics presenting to the ED by 49% and hospitalizations associated with these exacerbations by 60% compared to a placebo in a 12-week follow-up period.11 In summary, targeting eosinophil-high patients appears to hold the most promise for the anti-IL-5/IL-5R treatment strategy. A very recent proof-of-concept trial evaluated the GATA3-specific DNA enzyme SB010 on early and late-phase allergen challenge responses in mild allergic asthmatics.12 SB010 cleaves GATA3 mRNA transcripts that, in turn reduces the downstream induction of GATA3-regulated genes, including IL-4, IL-5, and IL-13. The study showed that early- and late-phase responses were attenuated by 11% and 34%, respectively, after 28 days of inhaled SB010. Whether this strategy will have efficacy in severe asthma is currently unknown. TSLP is an epithelial-derived cytokine that induces the activation of innate and adaptive type 2 responses in human asthmatic airways, which was shown to have higher levels of TSLP compared to healthy controls.2 A double-blind placebo-controlled study investigated the effect of tezepelumab, a fully human anti-TSLP monoclonal antibody, on early and late asthmatic responses after an allergen challenge.13 The treatment groups showed a decrease in early- and late-phase FEV1 reduction as well as blood and sputum eosinophil counts and FeNO. The recent clinical data on the use of long-acting muscarinic receptor antagonist tiotropium in asthma are promising. A systematic review of tiotropium revealed a reduction in exacerbations as well as lung function improvements in severe asthmatics not optimally controlled on ICS/LABA.14 Type 2-low (Th2 low) asthmatics do not have unifying biomarkers but typically have later onset disease associated with neutrophilia, smoking, obesity, and infection.2 Unfortunately, recent strategies to target neutrophilic asthma have not yielded the same success as the novel therapies for Th2-high asthma. The tumor necrosis factor (TNF)-α receptor inhibitor etanercept demonstrated some improvement in AHR, lung function, and symptoms in a small number of severe corticosteroid-dependent asthmatics.2 The monoclonal antibody to TNF-α, infliximab, reduced asthma exacerbations in moderate asthmatics, but a subsequent double-blind placebo-controlled study using another humanized antibody to TNF-α, golimumab, did not demonstrate any improvement in FEV1 or reduction in asthma exacerbations. Importantly, an increase in systemic infections and malignancies led to the early termination of the trial.2 Neutrophilic asthma has been linked to higher ICS use and lower FEV1. CXCR2 is the receptor for IL-8 that mediates neutrophil migration to sites of inflammation. A CXCR2 receptor antagonist was developed to target neutrophilic asthma, but human studies did not demonstrate clinical benefit.2 More recently, anakinra, an IL-1 receptor antagonist, was shown to decrease airway neutrophilia in a proof-of-concept study of healthy controls challenged with inhaled LPS and maybe a future therapeutic strategy in those with neutrophilic asthma.15 Finally, brodalumab is an anti-IL-17 receptor antibody targeting the Th17 pathway that has roles in host defense and tissue neutrophilia.2 Unfortunately, brodalumab treatment in severe asthmatics did not show an improvement in clinical benefit compared to placebo even when multiple subset analysis was performed concerning ACQ score, FEV1, and symptoms.2 CONCLUSION The future of airway disease management is shifting toward a more individualized, biomarker-driven approach that combines cutting-edge biologics, small molecules, gene therapies, and advanced drug delivery systems. Leveraging novel technologies and a deeper understanding of airway pathophysiology will enable clinicians to achieve better disease control and improved quality of life for patients with chronic airway diseases.
Ravindran Chetambath (Sat,) studied this question.